Medherant: Difference between revisions
m spelling |
Remove deletion discussion templates and unavailable templates |
||
| (19 intermediate revisions by 15 users not shown) | |||
| Line 1: | Line 1: | ||
'''Medherant Ltd''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]]. | |||
'''Medherant Ltd''' is a British [[pharmaceutical company]] | |||
==History== | ==History== | ||
Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system. | Medherant Ltd was founded as a [[university spin-off]] by [[David Haddleton|Professor David Haddleton]] and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system. | ||
Started as a research project in Haddleton Group at the University of Warwick in 2013, the company | Started as a research project in Haddleton Group at the University of Warwick in 2013, the company has operated at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and had received over £15M investment by the end of 2025.{{fact|date=October 2026}} | ||
==Research== | ==Research== | ||
Using its research in [[bioadhesive]]s and [[polymer chemistry]], the company | Using its research in [[bioadhesive|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal |last=Efstathiou |first=Spyridon |last2=Nurumbetov |first2=Gabit |last3=Ross |first3=Andrew |last4=Li |first4=Yongguang |last5=Haddleton |first5=David M. |date=2024-04-22 |title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) |url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f |journal=Materials Advances |language=en |volume=5 |issue=8 |pages=3396–3410 |doi=10.1039/D3MA01104F |issn=2633-5409|doi-access=free }}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant - About Us |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref> | ||
Medherant is also developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]] | Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news |date=2023-04-03 |title=Menopause testosterone patch to begin trials |url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 |access-date=2025-10-24 |work=BBC News |language=en-GB}}</ref> which has shown excellent results to date.<ref>[https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results "Medherant announces positive Phase 1 clinical trial results"] ''warwick.ac.uk''. University of Warwick. Retrieved 2025-10-24.</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].{{fact|date=October 2026}} | ||
==References== | ==References== | ||
| Line 31: | Line 14: | ||
==External links== | ==External links== | ||
* [ | * [https://www.medherant.co.uk/ Medherant.co.uk] | ||
[[Category:University of Warwick]] | |||
[[Category:Companies based in Coventry]] | [[Category:Companies based in Coventry]] | ||
[[Category:Pharmaceutical companies of the United Kingdom]] | [[Category:Pharmaceutical companies of the United Kingdom]] | ||
[[Category:University spin-offs]] | |||
Latest revision as of 03:15, 5 October 2026
Medherant Ltd is a British pharmaceutical company, based in Coventry. The company is developing over-the-counter (OTC) and prescription transdermal patches for drug delivery.
History
Medherant Ltd was founded as a university spin-off by Professor David Haddleton and the University of Warwick in 2015 for the purpose of commercialisation of a novel drug delivery system. Started as a research project in Haddleton Group at the University of Warwick in 2013, the company has operated at the University of Warwick Science Park since March 2015 after securing an investment from the Mercia Fund Management in 2014 and had received over £15M investment by the end of 2025.[citation needed]
Research
Using its research in polyurea based pressure sensitive adhesives[1] and polymer chemistry, the company is working to introduce transdermal drug delivery patches via the transepidermal route.[2] Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no solvents for the fabrication process.[3]
Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women[4] which has shown excellent results to date.[5] Medherant has also been developing transdermal analgesic patches for pain relief, based on nonsteroidal anti-inflammatory drugs (NSAIDs), e.g. ibuprofen, lidocaine, diclofenac and methyl salicylate.[citation needed]
References
- ↑ Efstathiou, Spyridon; Nurumbetov, Gabit; Ross, Andrew; Li, Yongguang; Haddleton, David M. (2024-04-22). "Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD)" (in en). Materials Advances 5 (8): 3396–3410. doi:. ISSN 2633-5409. https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f.
- ↑ "Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin". University of Warwick. https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/. Retrieved on 16 October 2016.
- ↑ "Medherant - About Us". Medherant Ltd. http://www.medherant.co.uk/about-us. Retrieved on 16 October 2016.
- ↑ "Menopause testosterone patch to begin trials" (in en-GB). BBC News. 2023-04-03. https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981.
- ↑ "Medherant announces positive Phase 1 clinical trial results" warwick.ac.uk. University of Warwick. Retrieved 2025-10-24.